VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.



Lexogen's QuantSeq 3' mRNA-Seq is a straightforward, fast, and cost-efficient method for library preparation. It has been widely used for expression profiling analysis and is currently featured in more than 470 publications. "QuantSeq is a well-established library preparation kit, validated by researchers who have used it for a broad range of applications. We are continuously enhancing the workflow based on the user feedback, and offering a complete solution including data analysis has always been top priority", said Dalia Daujotyte, Chief Commercial Officer at Lexogen.

As a platform for scientists, ROSALIND empowers QuantSeq 3' customers to analyze, interpret and collaborate globally on differential gene expression analysis without the need for specialized bioinformatics or programming skills. "Through our collaborations, it is our goal to provide full transcriptome analysis solutions vetted by experts in their fields. Access to QuantSeq data processing on ROSALIND not only gives an opportunity to an in-depth gene expression analysis, but also enables collaboration and multi-omics work without leaving the environment", added Daujotyte.

"QuantSeq 3' has been a game-changer for our biotech and pharma clients adopting RNA-seq, with the compelling economics to support high volume and the ability to assess the whole transcriptome," said Tim Wesselman, CEO of OnRamp Bio.

"With ROSALIND, QuantSeq users of every skill level are empowered to visually explore same day results, save valuable time and restore the thrill of discovery," added Wesselman.

The usage of ROSALIND for QuantSeq data analysis and interpretation was demonstrated during the GenomeWeb webinar "Integration of 3'mRNA-Seq and ChIP-Seq Datasets to Disentangle Redundant Epigenetic Regulatory Mechanisms", on June 18, 2020.

Access the Lexogen Multi-Omics Showcase at:

About Lexogen

Established in 2007, Lexogen is a transcriptomics and Next-Generation Sequencing company, focusing on the development of innovative methods for RNA analysis. Its portfolio includes multiple innovative and well-established protocols for RNA sequencing sample preparation, external RNA spike-in controls, as well as bioinformatics tools and sequencing services. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, US.

To learn more, visit and follow @lexogen.


Related Posts

  • For Scientists on ROSALIND: Collaborating on Genomic Data is a walkthrough on how to set up real-time collaboration on genomic data (like Google Docs). Read the post here. 
  • For Directors and Managers: The Value is in Collaboration (not the pipeline) discusses how collaboration is key to empowering research in your lab.
  • For every researcher, we have forever transformed Public Data exploration. Follow this link for more information.
  • To learn more about the latest capabilities, supported species and levels of access visit this post on how we are empowering scientists. 



Tim Wesselman

Written by Tim Wesselman

Tim Wesselman is Founder of Rosalind (formerly OnRamp Bio) and CEO since 2013. For the 20 years prior to starting Rosalind, Tim had been dedicated to understanding next-generation servers and storage solutions. Serving as Vice President at Hewlett-Packard, he led strategy & partnerships with the market leaders in big data software, advanced processors and cloud computing. These partners included known names, like FaceBook, MapR, Cloudera and DataStax with solutions that companies like Apple, Amazon, Microsoft, Baidu and many others heavily rely on today. Seeing the opportunity to bring this knowledge of advanced computing technology into the healthcare space, Tim founded and launched Rosalind to empower researchers, doctors and drug developers to accelerate genomic discoveries through collaboration so that we all can realize the promise of precision medicine and unlock biology's greatest unknowns.